BIIB241129P90000
- 0.10
- 0.000.00%
Biogen Newsroom
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials Driving The Negative Sentiment?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
Biogen Price Target Lowered to $207 From $251 at Mizuho
Optimism Over Global Healthcare Sector Rises: Jefferies
Biogen Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $207
European Commission Approves Samsung Bioepis, Biogen's Biosimilar Opuviz
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Mizuho Securities Adjusts Price Target on Biogen to $207 From $251
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data in Moderate-To-Severe Systemic Lupus
UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference